Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07001332Not ApplicableRecruiting

ELEVATE High-Risk PCI Pivotal Study

Role: lead

NCT07293923Not ApplicableRecruiting

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

Role: lead

NCT06099548Not ApplicableActive Not Recruiting

Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients

Role: lead

NCT05727059Not ApplicableCompleted

Magenta Elevate™ EFS in High-Risk PCI Patients

Role: lead

NCT03621436Not ApplicableTerminated

Clinical Evaluation of the TRVD™ System in ADHF

Role: lead

All 5 trials loaded